Posted by Michael Wonder on 24 Jul 2019
Patients, backed by ‘dark money’ group, get ready to debate Duchenne drug prices. It will not be boring.
24 July 2019 - Meetings of the Institute for Clinical and Economic Review don’t usually get one’s heart pumping.
But a meeting Thursday at the Massachusetts Institute of Technology may prove to be the exception to that rule.
Patients Rising Now, an advocacy group that says it promotes transparency in health care and that is a fierce opponent of ICER’s, is expected to face off with the self-professed “watchdog of drug pricing” as it reviews three drugs for Duchenne muscular dystrophy.
